Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $161

Benzinga · 1d ago
Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $160 to $161.